Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This trial is a single center, double blind, placebo-controlled trial in healthy male and female recreational cannabis users with placebo and AEF0117 dosed in a fixed sequence.
The goal of this clinical trial is to investigate if AEF0117 has any effect on the pharmacokinetics of THC and its metabolites when smoking cannabis.
Full description
The goal of this clinical trial is to investigate if AEF0117 has any effect on the pharmacokinetics of THC and its metabolites when smoking cannabis.
Participants will be male or female in good health aged from 21y to 55y old and who are recreational cannabis users.
The participant will receive either AEF0117 (2 mg) or placebo. The sponsor team, the research staff and the participant won't know which study medication has been given.
The main objectives of the trial are:
The participant will come for 2 inpatient phases (including one overnight stay). Those 2 inpatient phases are separated by 5 days at home.
After a screening period assessing the good health and the eligibility of the participant, on day 1 they will receive 2 capsules of the study medication and will smoke one cannabis cigarette. During the day, blood samples will be collected at defined timepoints before the study medication, after the study medication and before smoking and after smoking.
On day 2, Blood samples will be collected before and after the study medication intake.
At the end of the assessements, the participant will be discharged. They could be requested to stay at the research facility if they experience any adverse effects From Day 3 to Day 7, the participant will be contacted by phone or by videoconference to confirm the study medication intake and if they experience any adverse events.
On day 8, the participant will come back to the research facility for a 2 days visit including an overnight stay. Assessments and procedures will similar to those performed on Day 1 and Day 2.
On Day 14, the participant will come back to the research facility a last time for a final blood collection.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Healthy males and females of any race, 21 to 55 years old, both inclusive.
Subjects must use highly effective contraception.
Body mass index (BMI) between 20.0 and ≤35.0 kg/m2 at screening.
Be informed of the nature of the trial and provide written informed consent.
Be legally competent and able to communicate effectively (in English) with trial personnel.
Cannabis smoker (use ≥1 day the last 2 months and ≤2 days/week) who agrees to abstain from cannabis (except for what is provided by investigators) for 3 days prior to and including Day 1 and Day 8 of the study, and while in the clinic.
Exclusion criteria
Severe learning disability, brain damage, or pervasive developmental disorder.
Any disease or condition that according to the investigator's medical judgment might compromise the cardiovascular, hematologic, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems.
Any clinical laboratory values assessed as clinically significant by the investigator.
a) A history of alcohol- or substance use disorders within the past 2 years, recent or current regular use of any illicit drugs except cannabis. In case of a positive drug screen (except for cannabis) at screening, a negative test is required at re-screening.
b) The alcohol breath test and urine drug screen at predose Day 1 must be negative (including for cannabis, a level of THC-COOH <100 ng/mL is allowed).
A history of or current serious mental illness including active or recent suicidal ideation, severe psychological distress (e.g., active suicidal plans, psychosis, debilitating panic disorder), and/or an abnormal Columbia-Suicide Severity Rating Scale (C-SSRS) result (i.e., a C-SSRS score of ≥3).
History of COVID-19 within 4 weeks prior to Day 1, or positive COVID 19 test if required according to standard procedures at the site.
A history of difficulty donating blood or inadequate venous access.
Blood pressure outside normal range (140/80 mmHg systolic/diastolic) and considered potentially clinically significant by the investigator.
A corrected QT interval (Fridericia's correction, QTcF) >450 msec for males and >470 msec for females.
Clinically significant anemia or low hemoglobin (levels <9 g/dL) at screening, donation of >250 mL of blood or plasma or received any blood and plasma for medical/surgical reasons within the 30 days prior to receiving trial drug, or intention to donate blood or plasma within 1 month after receiving trial drug.
Allergies to the trial drug and known allergies to corn or corn derivatives.
Use of any prescription or over-the-counter drug therapy, including psychoactive and/or psychotropic medication, herbal or homeopathic supplements unapproved by the sponsor within 2 weeks prior to receiving the trial drug (for drugs with an elimination half-life greater than 10 days, this will be extended to 60 days).
Use of bodybuilding supplements, any food supplement or topical product containing pregnenolone, or any other steroid, including phytosteroids.
Use of a diet or supplements (e.g., St. John's Wort), or food and fruit juices (e.g., grapefruit juice, Sevilla oranges) known to induce or inhibit hepatic drug metabolism within 2 weeks prior to receiving the trial drug and until the follow-up visit, unless approved by the sponsor's medical monitor.
Tobacco smokers who smoke more than 5 cigarettes per day or use an equivalent daily amount of other tobacco products and are not willing to abstain from tobacco smoking during the inpatient visits.
Legal status that would interfere with participation.
Unable to follow the restrictions outlined in the protocol.
Use of an investigational drug or product, or participation in a drug trial within the last 90 days prior to receiving the trial drug.
Participation in a previous trial with AEF0117 within the last 3 months prior to screening.
Primary purpose
Allocation
Interventional model
Masking
24 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Meg Haney, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal